Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

An oral alternative to injectable treatment for uncomplicated gonorrhoea could be on the way in the US, as FDA starts review of GSK's gepotidacin.

The FDA has launched a programme to make it easier for drug companies to set up manufacturing facilities in the US and reduce the country's reliance on imported medicines. Today, the regulator ...

Brain-computer interface firm Neuralink has completed a $650m financing that it says will help to "bring our technology to more people" ...

A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.

Artificial intelligence specialist Artera has won FDA approval for AI-powered software that can help guide the management of patients diagnosed with localised prostate cancer. ArteraAI Prostate is ...

EVERSANA has launched a new pharmacovigilance platform to answer the need for advanced analytics and AI in drug safety monitoring and risk management.

The UK life sciences raised £1.23bn in venture capital investment in the first half of 2025, although there was a fallback in the second quarter.

Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.